According to IQVIA sales data for the 12-month period ending October 2022, the Cardene Capsules, 20 mg and 30 mg market achieved annual sales of approximately US $10.9 million
According to IQVIA sales data for the 12-month period ending September 2022, the Gilenya Capsules, 0.5 mg market achieved annual sales of approximately US $1.8 billion
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
MINYM can be safely used by patients above 9 years of age.
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
U.S. FDA has issued Form 483 with six observations after an inspection of the company’s formulation manufacturing facility based out of Baddi
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
A total of five observations for Goa and 17 for Monroe
Glenmark’s current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 46 ANDA’s pending approval with the U.S. FDA
The company has 47 ANDA's pending approval with the U.S.FDA
Subscribe To Our Newsletter & Stay Updated
